whitepaper
ebook: Proactive clinical supply planning
The importance of thoroughly planned resupply strategies in maintaining clinical supply inventories as studies move into late phase.
List view / Grid view
Gene therapy
article
Early phase CGT trials: key design elements correlating to distinctive biological characteristics
With increasing numbers of cell and gene therapies (CGTs) entering clinical trials, Dr Dave Li and Dr Anna Baran of KCR Consulting discuss how the biological characteristics of CGTs should be taken into account with early phase trial designs.
whitepaper
ebook: Early drug development strategies for clinical success
Learn the benefits of collaboration between the pharmaceutical scientists and clinical supply services teams.
news
Rise of biologics set to continue, says report
According to a new report, biologics are forecast to have $120 billion greater sales than small molecules by 2027.
news
Orphan drug sector continues to experience rapid growth
According to a new report, the orphan drug market is growing more than twice as fast as the non-orphan market and, by 2026, orphan drug sales will account for 20 percent of all prescription drug sales.
video
On-demand webinar: Mould contamination, investigation and remediation challenges
Most industries face mould contamination issues, including medical products, hospitals, cosmetics, paint, among others. Learn more about mould and what you can do to combat it.
news
Achilles Therapeutics expands manufacturing in the UK
The scale up in annual capacity and expansion of Achilles' global clinical manufacturing footprint will see its second site in the UK and first site to be established in the US.
article
The future of CMC for novel therapies
Novel and advanced therapies have come on in leaps and bounds over the past decade. Some cell and gene therapies have already reached the approvals stage, while others have now entered the later development stages. As a result, manufacturing process consistency, GMP standards and more must now meet more formal…
article
Bioprocessing/Bioproduction In-Depth Focus 2022
Download this in-depth focus to discover why closed systems and process automation are key for industrialised autologous cell therapy manufacturing and how CMC strategies for cell and gene therapies need to evolve.
![Recipharm logo on building in Bordeaux, France[Credit: sylv1rob1/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Recipharm-300x278.jpg)
![Recipharm logo on building in Bordeaux, France[Credit: sylv1rob1/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Recipharm.jpg)
news
Recipharm builds biologics presence with acquisitions
The closing of two biologics acquisitions will help Recipharm establish itself in the advanced therapy medicinal products space.
news
Catalent acquires new biologics facility in the UK
Catalent announces the expansion of its biologics development and manufacturing capability by purchasing a new facility, currently under construction in Oxford, UK.
news
FUJIFILM acquires new cell therapy manufacturing facility
FUJIFILM Diosynth Biotechnologies will run the cell therapy manufacturing facility, acquired for $100mn from Atara Biotherapeutics, as part of its global network.
news
Gene therapy shows promise in Wiskott–Aldrich syndrome
Lentiviral gene therapy reduces infections and bleeding episodes in children with a severe immune disorder Wiskott–Aldrich syndrome (WAS), finds new study.
news
UK cell and gene therapy manufacturing challenge ends in success
In a £1.3 million collaborative project Symbiosis and the Cell and Gene Therapy (CGT) Catapult reduced viral vector manufacturing times by more than 25 percent.
news
Catapult presents vision for UK’s cell and gene therapy future
To ensure the UK’s prominence in the cell and gene therapy arena, the CGT Catapult has published a roadmap for the research and adoption of these cutting-edge therapies.
